{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:06:09Z","timestamp":1788401169768,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.vaccine.2018.04.035","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T01:52:39Z","timestamp":1524189159000},"page":"2978-2984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever"],"prefix":"10.1016","volume":"36","author":[{"given":"So Jung","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puthupparampil V.","family":"Scaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Barnafo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Muratova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Hwa","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.04.035_b0005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/1475-2875-10-378","article-title":"A new world malaria map: Plasmodium falciparum endemicity in 2010","volume":"10","author":"Gething","year":"2011","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2018.04.035_b0010","first-page":"133","article-title":"Concurrent malaria and typhoid fever in the tropics: the diagnostic challenges and public health implications","volume":"45","author":"Uneke","year":"2008","journal-title":"J Vector Borne Dis"},{"key":"10.1016\/j.vaccine.2018.04.035_b0015","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale","year":"2014","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.vaccine.2018.04.035_b0020","unstructured":"World malaria report 2015; World Health Organization: Geneva, Switzerland."},{"key":"10.1016\/j.vaccine.2018.04.035_b0025","doi-asserted-by":"crossref","first-page":"010401","DOI":"10.7189\/jogh.01.010401","article-title":"Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010","volume":"2","author":"Buckle","year":"2012","journal-title":"J Glob Health"},{"key":"10.1016\/j.vaccine.2018.04.035_b0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/415673a","article-title":"The pathogenic basis of malaria","volume":"415","author":"Miller","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.04.035_b0035","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1365-3156.2008.02031.x","article-title":"Typhoid fever in children in Africa","volume":"13","author":"Mweu","year":"2008","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2018.04.035_b0040","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/ije\/dyl027","article-title":"The burden of malaria mortality among African children in the year 2000","volume":"35","author":"Rowe","year":"2006","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2018.04.035_b0045","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/cid\/cis024","article-title":"Typhoid Fever and the Challenge of Nonmalaria Febrile Illness in Sub-Saharan Africa","volume":"54","author":"Crump","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.035_b0050","first-page":"22","article-title":"Coinfection of typhoid and malaria","volume":"2","author":"Pradhan","year":"2011","journal-title":"J Med Lab Diagnosis"},{"key":"10.1016\/j.vaccine.2018.04.035_b0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1741-7015-12-31","article-title":"Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review","volume":"12","author":"Church","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2018.04.035_b0060","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/infdis\/165-Supplement_1-S49","article-title":"Thymus-independent and thymus-dependent responses to polysaccharide antigens","volume":"165","author":"Stei","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.035_b0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.152.2.361","article-title":"Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates","volume":"152","author":"Schneerson","year":"1980","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.04.035_b0070","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/infdis\/161.5.821","article-title":"Polysaccharide-protein conjugates: a new generation of vaccines","volume":"161","author":"Robbins","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.035_b0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.035_b0080","doi-asserted-by":"crossref","unstructured":"Chinnasami B, Sadasivam K, Vivekanandhan A, Arunachalam P, Pasupathy S. A Study on Longevity of Immune Response after Vaccination with Salmonella Typhi Vi Conjugate Vaccine (Pedatyph) in Children. J Clin Diagn Res 2015;9:SC01-3.","DOI":"10.7860\/JCDR\/2015\/13302.5903"},{"key":"10.1016\/j.vaccine.2018.04.035_b0085","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1586\/14760584.2013.845529","article-title":"Development of Vi conjugate - a new generation of typhoid vaccine","volume":"12","author":"Szu","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.04.035_b0090","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2018.04.035_b0095","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/iai.65.6.2088-2093.1997","article-title":"Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker","volume":"65","author":"Kossaczka","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.04.035_b0100","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.vaccine.2011.12.046","article-title":"Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine","volume":"30","author":"An","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.035_b0105","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1016\/j.vaccine.2011.08.019","article-title":"Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity","volume":"29","author":"An","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.035_b0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2018.04.035_b0115","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.vaccine.2015.01.061","article-title":"Preparation and testing of a Haemophilus influenzae Type b\/Hepatitis B surface antigen conjugate vaccine","volume":"33","author":"An","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.035_b0120","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.vaccine.2014.12.032","article-title":"A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi","volume":"33","author":"Kothari","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.035_b0125","doi-asserted-by":"crossref","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015;386:31-45.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"10.1016\/j.vaccine.2018.04.035_b0130","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","article-title":"Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines","volume":"33","author":"Richie","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.035_b0135","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1586\/14760584.2016.1141680","article-title":"Progress and prospects for blood-stage malaria vaccines","volume":"15","author":"Miura","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.04.035_b0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12936-016-1163-3","article-title":"Transmission-blocking strategies: the roadmap from laboratory bench to the community","volume":"15","author":"Gon\u00e7alves","year":"2016","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2018.04.035_b0145","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1084\/jem.174.5.1203","article-title":"Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals","volume":"174","author":"Barr","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.04.035_b0150","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.micinf.2007.02.011","article-title":"Malaria transmission-blocking vaccines: the bonus of effective malaria control","volume":"9","author":"Sauerwein","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2018.04.035_b0155","doi-asserted-by":"crossref","unstructured":"A research agenda for malaria eradication: Vaccines. The malERA consultative group on vaccines Plos Med 2011;8:e1000398.","DOI":"10.1371\/journal.pmed.1000398"},{"key":"10.1016\/j.vaccine.2018.04.035_b0160","doi-asserted-by":"crossref","first-page":"0163144","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and Immunogenicity of Pfs25-EPA\/Alhydrogel(R), a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naive Adults","volume":"11","author":"Talaat","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.04.035_b0165","doi-asserted-by":"crossref","first-page":"e2636","DOI":"10.1371\/journal.pone.0002636","article-title":"Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51","volume":"3","author":"Wu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.04.035_b0170","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1016\/j.vaccine.2013.04.034","article-title":"Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle","volume":"31","author":"Shimp","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.035_b0175","doi-asserted-by":"crossref","first-page":"e0190312","DOI":"10.1371\/journal.pone.0190312","article-title":"Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity","volume":"12","author":"Scaria","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.04.035_b0180","doi-asserted-by":"crossref","first-page":"18243","DOI":"10.1073\/pnas.0608545103","article-title":"Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex","volume":"103","author":"Wu","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2018.04.035_b0185","doi-asserted-by":"crossref","first-page":"e79538","DOI":"10.1371\/journal.pone.0079538","article-title":"A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice","volume":"8","author":"Jones","year":"2013","journal-title":"PLoS One"},{"issue":"39","key":"10.1016\/j.vaccine.2018.04.035_b0190","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1016\/j.vaccine.2015.08.025","article-title":"Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles","volume":"33","author":"Kumar","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.035_b0195","doi-asserted-by":"crossref","first-page":"e0138761","DOI":"10.1371\/journal.pone.0138761","article-title":"A Method for Producing Protein Nanoparticles with Applications in Vaccines","volume":"11","author":"Jones","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.04.035_b0200","doi-asserted-by":"crossref","first-page":"40312","DOI":"10.1038\/srep40312","article-title":"Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate","volume":"7","author":"Radtke","year":"2017","journal-title":"Sci Repm"},{"key":"10.1016\/j.vaccine.2018.04.035_b0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jbiotec.2008.02.017","article-title":"Carbis R Optimization of Vi capsular polysaccharide production during growth of Salmonella enterica serotype Typhi Ty2 in a bioreactor","volume":"135","author":"Jang","year":"2008","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2018.04.035_b0210","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jbiotec.2005.08.025","article-title":"Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris","volume":"121","author":"Tsai","year":"2006","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2018.04.035_b0215","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.vaccine.2007.10.064","article-title":"Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines","volume":"26","author":"Miura","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.035_b0220","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.vaccine.2013.02.006","article-title":"A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned","volume":"31","author":"Szu","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.035_b0225","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.micpath.2016.05.013","article-title":"Serum bactericidal assay for the evaluation of typhoid vaccine using a semi-automated colony-counting method","volume":"97","author":"Jang","year":"2016","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2018.04.035_b0230","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.04.035_b0235","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2017.04.078","article-title":"Polysaccharide conjugate vaccine protein carriers as a \u201cneglected valency\u201d - Potential and limitations","volume":"35","author":"Br\u00f6ker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.04.035_b0240","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/00006454-199008001-00004","article-title":"IgG subclass distribution of antibodies to bacterial and viral antigens","volume":"9","author":"Ferrante","year":"1990","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.04.035_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.04.035_b0250","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.1016\/j.vaccine.2012.05.081","article-title":"Immunization with the conjugate vaccine Vi-CRM197 against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice","volume":"30","author":"Fiorino","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18305188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:26:33Z","timestamp":1759400793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18305188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":50,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0264410X18305188"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}